$VRXA News
Last published 4w ago
- 4w agoVRXAVERAXA Biotech Presents in vivo Proof-of-Concept Data for BiTAC®-ADC Technology at World ADC CongressGlobeNewswireZURICH, SWITZERLAND – October 13, 2026 -- VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA")), an emerging leader in designing novel cancer therapies, today presented first in vivo proof-of-concept data and additional in
- 1mo agoVRXAVERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D StrategyGlobeNewswireZURICH, SWITZERLAND, Oct. 07, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA" or the "Company")), a leading developer of next-generation antibody-based cancer therapies, today
- 2mo agoVRXAVERAXA Biotech Appoints Raju Willener as Chief Financial OfficerGlobeNewswireZurich, Switzerland, Sept. 04, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA" or the "Company")), a leading developer of next-generation antibody-based cancer therapies, today
- 2mo agoVRXAVERAXA Biotech and Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate (AOC) AllianceGlobeNewswireZURICH, SWITZERLAND, and MARTINSRIED/MUNICH, GERMANY, Aug. 24, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA")), an emerging leader in the design and development of next-generation cancer
- 3mo agoVRXAVERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product CandidatesGlobeNewswireZURICH, SWITZERLAND, July 29, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA")), an emerging leader in designing novel cancer therapies, today provided an update on its core patent portfolio.
- 3mo agoVRXAOABIVERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAbGlobeNewswireZURICH, SWITZERLAND, July 27, 2026 -- VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA" or the ", Company", )), an emerging leader in designing novel cancer therapies, today announced the advancement of
- 3mo agoVRXAVERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future GrowthGlobeNewswireZURICH, SWITZERLAND , July 24, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA")), an emerging leader in the design and development of next-generation cancer therapeutics, held an
- 3mo agoVRXAVERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC® Technology Platforms and PortfolioGlobeNewswireZURICH, SWITZERLAND, July 23, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA")), an emerging leader in designing novel cancer therapies, today announced the appointment of Christoph Erkel,
- 3mo agoVRXAVERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development PlanGlobeNewswireZURICH, SWITZERLAND – July 20, 2026 – VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA)), an emerging leader in designing novel cancer therapies, today announced that it has received Scientific Advice from the German
- 4mo agoVRXAVERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® PipelineGlobeNewswireZURICH, SWITZERLAND – July 13, 2026 -- VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA")), an emerging leader in designing novel cancer therapies, today announced a collaboration with Ardigen S.A., an AI-driven
- 4mo agoVRXAVERAXA Biotech AG Appoints Carl von Halem as Interim Chief Financial Officer and Successor to Torsten BürgermeisterGlobeNewswireZURICH, SWITZERLAND – July 10, 2026 -- VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA")), an emerging leader in designing novel cancer therapies, today announced the appointment of Carl von Halem as Interim Chief
- 4mo agoVRXAVERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development TimelinesGlobeNewswireZURICH, SWITZERLAND – July 6, 2026 -- VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA")), an emerging leader in designing novel cancer therapies, today provided a company and pipeline update. "In the first six
- 4mo agoVRXAVERAXA Biotech Initiates Cell Line Development with ATUM to Advance its Lead BiTAC®-TCE ProgramGlobeNewswireZURICH, SWITZERLAND – July 02, 2026 -- VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA")), an emerging leader in designing novel cancer therapies, today announced the initiation of cell line development for its lead
- 4mo agoVRXAVERAXA Biotech Expands R&D Hub in Heidelberg as Innovative BiTAC™-TCE and ADC Programs Advance Towards Clinical DevelopmentGlobeNewswireZURICH, SWITZERLAND – June 24, 2026 -- VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA")), an emerging leader in designing novel cancer therapies, today announced that the Company has moved into additional laboratory
- 4mo agoVRXAVERAXA Biotech Establishes in vitro Proof-of-Concept for Novel BiTAC-ADC Technology Platform and Launches Partnering Discussions at BIO International Convention 2026GlobeNewswireZURICH, SWITZERLAND – June 18, 2026 -- VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA")), an emerging leader in designing novel cancer therapies, today announced that the Company has generated new in vitro proof-of-concept data
- 5mo agoVACHVRXAVERAXA Biotech to Debut as a Publicly Traded Company Pioneering Next-Generation Cancer Therapies on June 11, 2026GlobeNewswireBusiness combination transaction with Voyager Acquisition Corp. complete, creating a Nasdaq-listed, innovative biopharmaceutical company focused on next-generation cancer therapies of novel bispecific T-cell engagers